Bradley Sitko Buys 4,134 Shares of XOMA Co. (NASDAQ:XOMA) Stock

XOMA Co. (NASDAQ:XOMA) CIO Bradley Sitko bought 4,134 shares of the stock in a transaction that occurred on Friday, March 21st. The stock was acquired at an average price of $23.89 per share, for a total transaction of $98,761.26. Following the acquisition, the executive now directly owns 10,484 shares in the company, valued at $250,462.76. The trade was a 65.10 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Bradley Sitko also recently made the following trade(s):

• On Wednesday, January 8th, Bradley Sitko acquired 313 shares of XOMA stock. The stock was bought at an average cost of $25.60 per share, with a total value of $8,012.80.
• On Tuesday, December 31st, Bradley Sitko bought 300 shares of XOMA stock. The shares were bought at an average cost of $25.90 per share, for a total transaction of $7,770.00.

XOMA Trading Up 1.9 %

NASDAQ:XOMA opened at $21.13 on Thursday. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The firm’s 50 day moving average is $24.02 and its 200 day moving average is $26.99. XOMA Co. has a 12 month low of $19.92 and a 12 month high of $35.00. The stock has a market capitalization of $253.12 million, a PE ratio of -6.07 and a beta of 1.00.

XOMA (NASDAQ:XOMA) last posted its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The company had revenue of $8.70 million during the quarter, compared to the consensus estimate of $8.75 million. Sell-side analysts expect that XOMA Co. will post -1.41 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of XOMA. BNP Paribas Financial Markets grew its position in XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 795 shares in the last quarter. State Street Corp raised its stake in shares of XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after acquiring an additional 1,754 shares during the last quarter. Barclays PLC increased its stake in shares of XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 8,447 shares during the period. Geode Capital Management LLC increased its position in XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after purchasing an additional 1,138 shares during the period. Finally, Rhumbline Advisers lifted its position in shares of XOMA by 18.1% in the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 1,699 shares during the period. Hedge funds and other institutional investors own 95.92% of the company’s stock.

Analysts Set New Price Targets

XOMA has been the topic of several recent analyst reports. StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a research note on Friday, March 21st. HC Wainwright reiterated a “buy” rating and set a $104.00 price target on shares of XOMA in a report on Wednesday, March 19th.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.